Tempest to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Tempest Therapeutics (Nasdaq: TPST), a clinical-stage biotechnology company focused on developing targeted and immune-mediated cancer therapies, announced participation in two investor conferences.

Management will present at TD Cowen's 5th Annual Oncology Innovation Summit on May 29, 2024, at 2:00 p.m. ET and at the Jefferies Global Healthcare Conference on June 5, 2024, at 4:00 p.m. ET.

Recordings of these events will be available on the Tempest investor relations website.

Positive

• Participation in high-profile investor conferences can increase visibility and credibility.
• Engagement at these events may attract potential investors and partnerships.
• Showcases Tempest's commitment to transparency and communication with investors.

Negative

• No new financial or clinical data disclosed in the announcement.
• Potentially high expectations set without concrete updates might disappoint investors.

BRISBANE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classⁱ targeted and immune-mediated therapeutics to fight cancer, today announced that management will participate in the following upcoming investor conferences:

• TD Cowen's 5th Annual Oncology Innovation Summit – Fireside chat on Wednesday, May 29, 2024 at 2:00 p.m. ET
   
• Jefferies Global Healthcare Conference – Presentation on Wednesday, June 5, 2024 at 4:00 p.m. ET

To access the live or archived recording of the discussions, please visit the investor section of the Tempest website at https://ir.tempesttx.com.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Investor & Media Contacts

Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

i If approved by the FDA

FAQ

What upcoming investor conferences will Tempest Therapeutics (TPST) be participating in?

Tempest Therapeutics will participate in TD Cowen's 5th Annual Oncology Innovation Summit on May 29, 2024, and the Jefferies Global Healthcare Conference on June 5, 2024.

When is Tempest Therapeutics' presentation at TD Cowen's 5th Annual Oncology Innovation Summit?

Tempest Therapeutics will present at TD Cowen's 5th Annual Oncology Innovation Summit on May 29, 2024, at 2:00 p.m. ET.

When is Tempest Therapeutics' presentation at the Jefferies Global Healthcare Conference?

Tempest Therapeutics will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 4:00 p.m. ET.

Where can I access the recordings of Tempest Therapeutics' conference presentations?

Recordings of Tempest Therapeutics' conference presentations can be accessed in the investor section of the Tempest website at https://ir.tempesttx.com.